CN1782083A - Novel thrombase-like gene and its use - Google Patents
Novel thrombase-like gene and its use Download PDFInfo
- Publication number
- CN1782083A CN1782083A CN 200510036960 CN200510036960A CN1782083A CN 1782083 A CN1782083 A CN 1782083A CN 200510036960 CN200510036960 CN 200510036960 CN 200510036960 A CN200510036960 A CN 200510036960A CN 1782083 A CN1782083 A CN 1782083A
- Authority
- CN
- China
- Prior art keywords
- enzyme
- tle
- thrombin
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 241001505404 Deinagkistrodon acutus Species 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 7
- 206010008132 Cerebral thrombosis Diseases 0.000 claims abstract description 5
- 208000005189 Embolism Diseases 0.000 claims abstract description 5
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims abstract description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 238000005215 recombination Methods 0.000 claims description 13
- 230000006798 recombination Effects 0.000 claims description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 206010047249 Venous thrombosis Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 240000005708 Eugenia stipitata Species 0.000 claims description 2
- 235000006149 Eugenia stipitata Nutrition 0.000 claims description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims description 2
- 101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 abstract description 45
- 210000004907 gland Anatomy 0.000 abstract description 13
- 230000023555 blood coagulation Effects 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 6
- 230000023597 hemostasis Effects 0.000 abstract description 5
- 239000002435 venom Substances 0.000 abstract description 2
- 231100000611 venom Toxicity 0.000 abstract description 2
- 210000001048 venom Anatomy 0.000 abstract description 2
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 25
- 238000011160 research Methods 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 239000003998 snake venom Substances 0.000 description 16
- 108700012029 Agkistrodon acutus thrombin-like Proteins 0.000 description 15
- 231100000614 poison Toxicity 0.000 description 15
- 239000002574 poison Substances 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000270295 Serpentes Species 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 241000271897 Viperidae Species 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- -1 arginine ester Chemical class 0.000 description 4
- 230000001112 coagulating effect Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001723 fibrinogenic effect Effects 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000271039 Agkistrodon Species 0.000 description 3
- 108010027612 Batroxobin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241001532589 Trimeresurus stejnegeri Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000132536 Cirsium Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000271037 Crotalinae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241001478424 Hippocampus kuda Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 241001474977 Palla Species 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000271579 Trimeresurus gramineus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 108010024415 stejnobin Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000271517 Bothrops jararaca Species 0.000 description 1
- 101100016363 Caenorhabditis elegans his-67 gene Proteins 0.000 description 1
- 241001449342 Chlorocrambe hastata Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000271042 Gloydius halys Species 0.000 description 1
- 241001494884 Gloydius ussuriensis Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000561044 Halys Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102100038356 Kallikrein-2 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000143278 Macrovipera Species 0.000 description 1
- 241000271035 Macrovipera lebetina Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 241001487809 Protobothrops Species 0.000 description 1
- 241001487808 Protobothrops mucrosquamatus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 241000271577 Trimeresurus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 108010035158 arginine esterase Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Images
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention discloses a new kind of thrombin-like enzyme gene and its application. By means of RT-PCR process, thrombin-like enzyme gene tle, which has DNA sequence as shown in <400>1 sequence in the sequence list, is screened out from total RNA of Agkistrodon acutus venom gland. The gene coded proten thrombin-like enzyme (TLE) has amino acid sequence as shown in <400>2 sequence in the sequence list. The recombinant thrombin-like enzyme has both blood coagulation and hemostasis acitivity, and may be used in preparing medicine for treating vanous thrombosis, cerebral thrombosis and other vascular embolus diseases.
Description
Technical field
The present invention relates to a kind of new Thrombin-like enzyme Thrombin-like enzyme (TLE) and this proteic gene tle of coding, and the application of this albumen in vessel embolism medicines such as preparation treatment phlebothrombosis, cerebral thrombosis.。
Background technology
Agkistrodon acutus (Deinagkistrodon acutus, Gunther, 1888), belong to Viperidae (Viperidae), Crotalinae (Crotalinae), point kiss Pallas pit viper belongs to (Agkistrodon) unique kind, also cries Agkistrodon, Hundred-pace pit viper, Ji snake etc., and folklore goes on foot and will die as walking after being bitten by it less than 100.Be the distinctive snake kind of China, mainly be distributed in the vast mountain area on ground such as Fujian, each province, China south, Zhejiang, Hunan, Hubei, Jiangxi, Anhui, Guangdong, Guangxi and Taiwan.
People very early agkistrodon acutus as a kind of valuable medicinal, with dried the stimulating the circulation of the blood and cause the muscles and joints to relax of snake that it is made, spasmolysis is attacked effects such as poison.Have long and big pipe tooth, mainly contain the circulation of blood poison.The venom injection rate is big when hurting sb.'s feelings, and is with drastic toxicity, wound severe pain, and whole body can play bleeding blister.Because agkistrodon acutus is the peculiar snake kind of China, so the various research work of relevant agkistrodon acutus also mainly concentrate on China's (containing Taiwan Province).Research to sTLE also is so, from document, is Japanese scholar's research report though sub-fraction is arranged, and most of research report to sTLE all concentrates on China's Mainland and Taiwan.
The research of domestic relevant agkistrodon acutus snake venom, many earliest antidotes that bite with exploration snake venom toxicity and searching treatment are purpose.Research to the agkistrodon acutus Thrombin-like enzyme starts from the end of the seventies, and has progressively developed and have anti-freezing, go effect such as fibre and thrombolysis, is used for the treatment of sick fiber eliminating enzyme (and various predecessor) such as ischemic cerebrovascular, coronary heart disease and stenocardia.Even to this day, fiber eliminating enzyme still as outstanding domestic drug widespread use safely and efficiently clinically.Domestic short research of coagulating component is after the eighties in last century to relevant agkistrodon acutus Thrombin-like enzyme, and most research all inadequately comprehensively and deeply.Usefulness DEAE-Sephadex A-50 such as Liu Guangfen produce the agkistrodon acutus snake venom to Fujian and have carried out preliminary column chromatography analysis and activation analysis.Usefulness diethylaminoethylcellulose column chromatographies such as Zhang Hongji are divided into 15 components with the agkistrodon acutus snake venom, and enzyme activity, blood coagulation activity, fibrinolytic, hemorrhage poison and the toxicity etc. of each component are measured, find that the agkistrodon acutus snake venom contains the component of tool arginine ester enzymic activity, fibrinolytic and blood coagulation activity.Teng Guoqiang etc. separate the agkistrodon acutus snake venom of Wannan mountainous area with DEAE-Mierocrystalline cellulose DA22 column chromatography, get 15 protein peaks, and measured respectively each component relevant enzyme active and with shortly coagulate, the relation of anti-freezing, fibrinolytic, haemolysis, physiologically active such as hemorrhage, and think that short Blood clotting is to directly act on Fibrinogen, and with the arginine ester enzymic activity; The author has studied wherein some the enzyme activities of Thrombin-like enzyme class simultaneously, finds that it can act on Fibrinogen to specificity and make the clotting of plasma, does not need the participation of other thrombin, also is not subjected to the inhibition of heparin.Wang Qingchuan etc.
[58]The mixture of three kinds of isozymes of having studied the agkistrodon acutus Thrombin-like enzyme is found that its aggegation to the platelet suspension of people, dog or rabbit is inhibited, and is dosage correlation the influence of platelet aggregation function.Zhu Longxiang etc. have studied with ELASA microdetermination agkistrodon acutus Thrombin-like enzyme, and have carried out the research of the pharmacokinetics of these product as detection technique with this method.Zhou Sufang etc.
[58]Studied the setting time of external whole plasm of agkistrodon acutus Thrombin-like enzyme inductive and adsorbed plasma, different physico chemical factors are to the setting time (thrombintime of the external whole plasm of agkistrodon acutus Thrombin-like enzyme and thrombin induction, TT), KPTT (KPTT) and prothrombin time (prothrombjn time, influence PT).Liu Guangfen etc. have also carried out the long term toxicity of agkistrodon acutus Thrombin-like enzyme and the research of the pharmacological effect behind the successive administration.Though more than research provides a lot of useful data for we are familiar with sTLE, but these researchs rest on each component of separating is carried out on the mensuration and general research of enzyme activity more, lack further investigation its structure and characteristic; And employed isolation technique is also comparatively simple, can not obtain the pure product of one-component, or does not provide the purifying process and the characteristic of sample; In addition, only we can't judge that also these components are the component of anti-bolt anticoagulation on earth on pharmacology from these researchs, still short component of coagulating anastalsis.
Chinese Academy of Sciences's Dalian physical chemistry the usefulness ion-exchange such as Qian Yawen and the gel filtration method of Y.ZHANG etc. and Chinese University of Science and Technology from the agkistrodon acutus snake venom, obtain seven protein peaks that contain blood coagulation activity, with capillary electrophoresis these seven peaks are carried out further fine separation then, use the auxiliary laser desorption mass spectrometry of matrix (laser desorption/ionization massmonitoring again, LDIM) detect the molecular weight of each component, draw the molecular weight of the major protein at seven peaks.The prompting of above-mentioned result of study, the molecular weight of the agkistrodon acutus Thrombin-like enzyme in the certain molecular weight scope are included in above-mentioned each peak of listing in main and the less important proteic molecular weight.
Open your equality and produce the agkistrodon acutus snake venom, isolated a Thrombin-like enzyme that molecular weight is 15.1KD, and its physics and chemistry and zymologic property are studied from the Hunan; This component can make human plasma solidify rapidly, and can strengthen the effect of zymoplasm, thrombin time is shortened, so have hemostatic effect.From beginning in 1988, Xiao Changhua etc. delivered a series of articles, and what we can be comparatively detailed from these articles recognizes the short research train of thought of coagulating component of agkistrodon acutus Thrombin-like enzyme.Xiao Changhua etc. have carried out isolation and purification with DEAE-sephadex A-50 post, DEAE-cellulose DE52 post, QAE-sephadex A-25 post, SephadexG-25 post four one-step chromatographies to the agkistrodon acutus snake venom respectively, obtained four and had the active electrophoretically pure single albumen of arginine esterase, illustrating has four kind thrombin component in the agkistrodon acutus snake venom.He Lifen etc.
[43]Further studied the interior hemostatic effect of body of said components, adopt the hemorrhage hemostasis experiment of rabbit carotid artery and domesticated dog medium-sized artery damage ejection, rabbit liver parenchyma organ hemostasis experiment and domesticated dog dialysis hind leg hemostasis experiment, drawing it has anastalsis to rabbit and the experimental wound hemorrhage of domesticated dog.But regrettably above-mentioned experiment is that 30KD and 19.5KD two components are mixed in proportion the back as sample and usefulness, and the research respectively of its one-component is not reported.
The various researchs about snake venom thrombin-like enzyme abroad are extremely extensively and go deep into.Domestic present widely used imported medicine DF-521 and reptilase are exactly the representative of snake venom thrombin-like enzyme in anti-bolt and two application facet of hemostasis, and relevant basis and clinical study are also very deep.But for the correlative study of agkistrodon acutus Thrombin-like enzyme, particularly coagulate and hematostatic research about short, external and domestic the same extremely thin a little less than.Main overseas investigator is Taiwan and Japanese scholar.As far back as nineteen fifty-seven, Taiwan's scholars Ouyang just finds that Taiwan is produced in the agkistrodon acutus and contains the Thrombin-like enzyme composition, and the activity that confirms this Thrombin-like enzyme has procoagulant activity under the high dosage and an anticoagulating active under the low dosage external.Cheng.H etc. have inquired into the separating effect of different separation methods to the agkistrodon acutus Thrombin-like enzyme, some the enzyme activities of different chromatographic peaks have been measured, and studied the blood coagulation enhancing effect of agkistrodon acutus Thrombin-like enzyme and the relation between the enzymic activity, and confirm that the Thrombin-like enzyme activity is exactly the esterase effect of occurring in nature.Ouyang.C etc. have isolated the Thrombin-like enzyme that a kind of molecular weight is 24.1K in the agkistrodon acutus snake venom, and its physico-chemical property carried out preliminary research, find that it has fibrinoclase activity, fine former lytic enzyme activity and casein lytic activity, and it is confirm that its fibrinolytic is specificly to act on fibrinogenic α (A) chain, and inoperative to β (B) chain and γ chain.Equally, the former justice of a specified duration of China fir etc. are also produced the agkistrodon acutus snake venom from Taiwan and are isolated the Thrombin-like enzyme that a kind of molecular weight is 52K, this short component carbohydrate containing of coagulating, and the hydrolyzable arginine ester, as TAEE or TAME, but the indigestion casein.Should shortly coagulate with the arginine ester enzymic activity and can be suppressed by DFP and antiserum(antisera), but not by Trypsin inhibitor SBTI (STI), EDTA, halfcystine, heparin or pCMBA (PCMB) etc. suppress.
But about the agkistrodon acutus Thrombin-like enzyme there is no bibliographical information as the production and the service condition of hemostatic drug.
Contain a large amount of blood toxicities and enzyme resource in the agkistrodon acutus, but, traditional biochemical extracting method production cost height, product purity are low, add the shortage of the snake resource that going from bad to worse of global ecological environment brought, and have restricted the research and utilization of various enzyme components in the snake venom to a great extent.
The invention of agkistrodon acutus Thrombin-like enzyme Thrombin-like enzyme, be to find in the novelty of these species of agkistrodon acutus, it provides a good drug candidates, is very useful for preventing and treating vessel embolism such as human phlebothrombosis and cerebral thrombosis.
Summary of the invention
The object of the present invention is to provide a kind of new Thrombin-like enzyme Thrombin-like enzyme and this proteic gene tle of coding.
Another object of the present invention is to provide this proteic production method.
The 3rd purpose of the present invention is to provide the application of this albumen in vessel embolism medicines such as preparation treatment phlebothrombosis, cerebral thrombosis.
The present invention separates the thrombase-like gene tle that obtains with the method for RT-PCR from the total RNA of agkistrodon acutus poison gland, its dna sequence dna as in the sequence table<400〉1 sequences shown in.
The albumen Thrombin-like enzyme of genes encoding of the present invention, its aminoacid sequence as in the sequence table<400〉2 sequences shown in.Molecular weight is 26kD.
This albumen can be by recombination yeast with the excretory formal representation.
This albumen acts on the fibrinogenic A α chain specifically, has blood coagulation activity.
The selected agkistrodon acutus of the present invention picks up from Fujian Province's Wuyishan Nature Reserve.
The structure in agkistrodon acutus poison gland cDNA library: at first with the agkistrodon acutus broken end, anatomical isolation goes out fresh poison gland tissue fast, extracts total RNA.Reverse transcription is a synthetic double chain cDNA behind the chain cDNA, and double-stranded cDNA is connected back Transformed E .coli with the pcDNA3.0 carrier, and preserves each recombinant clone.
The present invention measures by above reorganization library clone being carried out extensive stochastic sequence, therefrom obtained the clone of a coding Thrombin-like enzyme, called after Thrombin-like enzyme (be called for short TLE), (its dna sequence dna as in the sequence table<400〉1 sequences shown in).New 236 amino acid whose mature peptides of genes encoding (its aminoacid sequence as in the sequence table<400〉2 sequences shown in), molecular weight is 26kDa, has typical Thrombin-like enzyme characteristics.Through bioinformatic analysis, a kind of new Thrombin-like enzyme of this genes encoding.It contain with conservative serine stretch protein enzyme catalysis three connect structures (H57, D102, S195), and near also high conservative of the sequence three amino acid of catalysis triplet.
The present invention is by a pair of primer of design, and the new gene tle of coding Thrombin-like enzyme is come out from pcDNA3.0 carrier amplification with PCR method, is cloned on the methanol yeast expression vector pPICZ α A, is built into expression plasmid and it is transformed pichia spp GS115.This expression vector is with P
AOX1Be promotor, adopt the form of secreting, expressing that recombinant protein is secreted in the fermentation supernatant.By to incubation time, induction time, the groping and optimize of conditions such as methanol concentration, the Recombinant Protein Expression amount can reach 1mg/L.
The present invention also gropes and has optimized the purification condition of recombination classes zymoplasm, and the fermentation supernatant can obtain purity at the ripe recombination classes zymoplasm Thermbin-like enzyme (TLE) more than 95% through Q sepharose FF anionresin column purification.
The recombination classes zymoplasm Thermbin-enzyme like biologically active that the present invention obtains.What this recombination classes zymoplasm was special acts on the fibrinogenic Aa chain, has blood coagulation activity.
By the expression plasmid pPICZ α A of Thermbin-like enzyme mature polypeptide coding sequence that contains of the present invention through XhoI/Not I double digestion, can obtain the fragment about 780bp, be agkistrodon acutus poison gland Thrombin-like enzyme Thermbin-likeenzyme mature polypeptide coding sequence.
The clone method of expression plasmid of the present invention:, press CaCl with reference to Sambrook (Sambrook, et al.1989, Molecular cloingCold Spring Harbor Labroratory Press.USA) method
2Method transforms plasmid in E.coli.DH5 α bacterial strain, with the LB substratum transform bacteria that contains penbritin (100 μ g/mL), alkaline process extracts plasmid.
Description of drawings
Fig. 1 is the comparison result of agkistrodon acutus poison gland Thrombin-like enzyme Thermbin-like enzyme of the present invention and other several homology Thrombin-like enzymes.The amino acid that dash (-) representative is identical, the amino acid of plus sige (+) representative disappearance.Tle1 is an agkistrodon acutus poison gland Thrombin-like enzyme; Halys is from Gloydius halys (gi:AF015727.1); Trimeresurus is from Trimeresurus gramineus (gi:2114123); Acutase has another name called Acuthrombin, from Deinagkistrodonacutus (gi:8567982); Agkistrodon and Dav-KN and Dav-PA are from Deinagkistrodon acutus[]; Ussuriensis and ussuriensis2 are from Gloydius ussuriensis (gi:2407644); Macrovipera is from Macrovipera lebetina (gi:6562943); Protobothrops is from Protobothrops mucrosquamatus (gi602601);
Fig. 2 is the total RNA electrophoresis result of agkistrodon acutus poison gland.
Fig. 3 is an agkistrodon acutus poison gland Thrombin-like enzyme tle Gene RT-PCR electrophoresis result.1:1kb DNA marker; 2:PCR purpose band.
Fig. 4 is the expression plasmid pPICZoA-tlePCR evaluation figure that contains gene tle.1:1kb?DNA?marker;2:Nativecontrol。3、4:Positive?transformants。
Fig. 5 is the recombinant expression plasmid pPICZoA-tle design of graphics that contains gene tle.
Fig. 6 dyes figure as a result for the expression and purification SDS-PAGE silver of delivering of Thrombin-like enzyme.1-5 is the fermentation supernatant of different periods: 5 for inducing back 12hr, and 1 is 24hr, and 2 is 36hr, and 3 is 36hr, and 4 is 72hr, and 6 is to express contrast (72hr) behind the empty carrier transformed yeast bacterium.8 is the result behind the Benzamidine purifying.
Fig. 7 lives for fibrinogen plate assay detects enzyme.Formed muddy spot behind the A:TLE Benzamidine purifying.B: the active spot that forms after the TLE behind the purifying dilutes 10 times.C: the active spot that forms after the TLE behind the purifying dilutes 50 times.
Fig. 8 is the research of Thrombin-like enzyme to substrate specificity.1, negative control does not add enzyme reaction solution; 2-13 is respectively in TLE effect 0.5min, 1min, 10min, 60min, 2hr, 4hr, 6hr, 8hr, 10hr, 12hr, 14hr, 16hr stopped reaction; 14, behind homemade fiber eliminating enzyme effect 2min; 15 be reptilase effect 2min after.
Embodiment
Following examples will help those of ordinary skill in the art further to understand the present invention, but not limit the present invention in any form.
Embodiment 1: the extraction of the total RNA of agkistrodon acutus poison gland and RT-PCR amplification
The extraction of total RNA and cDNA are synthetic: adopt a step hot phenol method to extract the total RNA of agkistrodon acutus poison gland, protein is removed in extracting.Obtaining total rna concentration is 3.9 μ g/ μ l, its A
260/ A
280=1.9, detect as seen 18s and 28s two bands clearly through 1% agarose electrophoresis, (see figure 2) shows that total RNA integrity is good.Get the total RNA of 1ug with SMART IIIolignuclotide (5 '-AAGCAGTGGTATCAACGCAGAGTGGCCATTATGGCCGGG-3 ') and CDSIII/3 ' PCR primer (5 '-ATTCTAGAGGCCGAGGCGGCCGACATG-d (T)
30N
-1N-3 ') each 1ul carries out synthetic first chain of reverse transcription, obtains 10 μ l cDNA, the first chain product.2 μ l, the first chain product is with 5 ' PCR primer (5 '-AAGCAGTGGTATCAACGCAGAGT-3 '), CDS III/3 ' PCR primer (5 '-ATTCTAGAGGCCGAGGCGGCCGACATGd (T)
30N
-1N-3 ') carries out the amplification of second chain.With carrying out Sfi I cutting behind second chain protease K digestion and the purifying, connect into same Sfi I enzyme and cut on the pcDNA3.0 carrier library of handling.The EST that random sequencing obtains thrombase-like gene finds that through software analysis this EST is a total length.
Embodiment 2: the sequential analysis of agkistrodon acutus poison gland thrombase-like gene
Blast homology analysis revealed, the stejnobin sequence of a kind of serine protease of the nucleotide sequence of the new gene of this agkistrodon acutus poison gland Thrombin-like enzyme and a kind of India green bamboo snake (Trimeresurus gramineus) and Chinese green bamboo snake (Trimeresurus stejnegeri) has 87% homology, and (Bathrops jararaca) has 86% homology with America spearhead Pallas pit viper.The coded aminoacid sequence of stejnobin of the protein sequence of TLE and Chinese Trimeresurus stejnegeri (Trimeresurus stejnegeri) has the highest homology (72%), what is interesting is, this TLE gene with originally be that the homology of reporting thrombase-like gene from agkistrodon acutus is not the highest, in 13 thrombase-like genes of the agkistrodon acutus of having reported, it and Acutobin precursor (Acuthrombin/Acutase) have the highest homology (68%).This TLE aminoacid sequence has the typical feature with the Thrombin-like enzyme of other snake venom, contains the conservative catalysis triplet of serine protease: His67, Asp112, Ser206.By sequence relatively, prove that TLE is a kind of new thrombase-like gene, tle gene ORF total length is 780bp, translates into 260 amino acid with zymogen forms, and wherein signal peptide has 18 amino acid, pre-peptide region has 6 amino acid, and mature peptide contains 236 amino acid.Its mature peptide molecular weight (not containing glycosyl) is 26kD.It contains 12 halfcystines, forms 6 pairs of disulfide linkage.
Embodiment 3: the structure of agkistrodon acutus Thrombin-like enzyme yeast secreted expression plasmid
According to the synthetic a pair of primer of two terminal sequences of tle gene, upstream primer contains Xho I cleavage site, and downstream primer contains the NotI cleavage site.
Upstream primer (B1):
-CCG
CTCGAGAAAAGAGAGGCTGAAGCTGTCATTGGAGGTAATGAATGTAAC-
Xho?I?3’end?ofα-Factor?signal?sequence Mature?TLE
Downstream primer (B2):
-TGC
TCTAGATAACTTCTTCAAAAGTTTTCACGG
With the pcDNA3.0 plasmid that contains the tle gene is template, and B1, B2 are the primer PCR amplification, obtains the single band of specific amplified, and the product size is (Fig. 3) about 122bp.PCR is about 800bp, and amplified production to pichia yeast expression vector pPICZ α A, obtains recombinant expression vector pPICZ α A-tle (its building process as shown in Figure 5) through Xho I/NotI enzyme cutting clone.Expression vector identifies that through PCR (see figure 4) is correct.Foreign gene among the expression vector pPICZ α A-tle is identified correct through order-checking.
Embodiment 4: the expression of agkistrodon acutus recombination classes zymoplasm
PPICZ α A-tle electric shock is transformed Pichi strain Gs115, obtain recombination yeast gene engineering fungus.This restructuring yeast strains is after methanol induction is expressed, and its fermented supernatant fluid is with Tricine/Tris SDS-PAGE electrophoretic analysis.The result shows that thalline has tangible specifically expressing product band after inducing, and its molecular weight (28kD) is bigger slightly than the theoretical value (26kD) of prediction, and supposition is glycosylated result (Fig. 6) in the yeast expression process.。
Process is groped conditions such as medium pH value, methanol induction concentration, induction time, has determined medium pH 5.5,3 days expression condition of induction time.
Embodiment 5: the purifying of agkistrodon acutus recombination classes zymoplasm
The fermented supernatant fluid that contains agkistrodon acutus recombination classes zymoplasm of embodiment 5 gained, change level pad (20mM Tris-HCl into through Sephadex G-25 post, 150mM NaCl pH8.0) after, go up the Benzamidine pillar that same damping fluid balance is crossed, reduce to 0 with this damping fluid flushing pillar to passing the peak again, use 500mM NaAc, 500mMNaCl (pH3.0) is wash-out directly, collect elution peak, use Tris-Hcl (pH8.0) neutralization of 500mM to be eluted to neutral pH immediately.Elution peak is TLE (Fig. 6) after SDS-PAGE detects.
Embodiment 6: recombinant expressed Thrombin-like enzyme is active to be detected
Adopt fibrinogen plate assay [Stocker K] to improve: 50mg agarose is dissolved in the 5ml physiological saline, be heated to 90 ℃ and make dissolving, be cooled to 45 ℃, add 5ml and be preheating to 45 ℃ 0.4% bovine fibrinogen (Nat'l Pharmaceutical ﹠ Biological Products Control Institute's system), mixing, a kind of rhyme scheme in Chinese operas serving as the prelude to a complete score for voices fast.After the cooling, punch on flat board, every hole adds 10 μ l testing samples, is just putting in 37 ℃ of moist environments and is spending the night, and observation has or not muddy spot to occur.The results are shown in Figure 7, recombinant expressed Thrombin-like enzyme has muddy spot to occur.
Embodiment 7: the low thing specific detection of recombination classes zymoplasm
Adopt the SDS-PAGE method: bovine fibrinogen is dissolved in the Tris-HCl solution of aseptic 0.02mol/L pH8.0 or the physiological saline (20mg/ml), getting 200 μ l transfers in the glass test tube, add isopyknic enzyme liquid, 37 ℃ of temperature are bathed, in different period termination reactions, sampling is handled and is carried out SDS-PAGE.The results are shown in Figure 8, recombinant expressed Thrombin-like enzyme is the same with fiber eliminating enzyme and reptilase, all is specific acting on the fibrinogenic A α chain.
Sequence table
<110〉Zhongshan University
<120〉a kind of new thrombase-like gene and application thereof
<160>2
<210>1
<211>711
<212>DNA
<213〉agkistrodon acutus (Hippocampus kuda Bleeker)
<220>
<221>mat?peptide
<222>(1)…(711)
<400>1
1 GTC?ATT?GGA?GGT?AAT?GAA?TGT?AAC?ATA?AAT?GAA?CAT?CGT?TTC?CTT?GTA?GCC?TTG?TAT?GAC 61
1 V I G G N E C N I N E H R F L V A L Y D 20
61 AAT?TTG?ACT?GGG?ACT?TTG?GAC?TGC?GGT?GGG?ACT?TTG?ATC?AAT?CAG?GAA?TGG?GTG?CTC?AGC?121
21 N L T G T L D C G G T L I N Q E W V L S 40
121?GCT?GCA?CAC?TGC?GAC?AGG?ACA?AGT?GTG?GTC?ATA?TAC?CTT?GGT?ATG?CAT?AAC?AAA?AGT?GTA?181
41 A A H C D R T S V V I Y L G M H N K S V 60
181?AAC?AAT?GAC?GAT?CAG?CAG?AGA?AGA?TCC?CCA?AAG?GAG?AAG?TAC?TTT?TTT?AAC?TGT?AGC?AAT?241
61 N N D D Q Q R R S P K E K Y F F N C S N 80
241?AGC?TTT?ACC?CAA?CTG?GAA?AAG?GAC?ATC?ATG?TTG?ATC?AGG?CTG?GAC?AGT?CCT?GTT?AAC?AAC?301
81 S F T Q L E K D l M L I R L D S P V N N 100
301?AGT?ACA?CAC?ATC?GCG?CCT?CTC?AGC?TTG?CCT?TCC?AGC?CCT?CCC?AGT?ATG?GAC?TCA?GTT?TGC?361
101?S T H I A P L S L P S S P P S M D S V C 120
361?CGT?GTT?ATG?GGA?TGG?GGC?GCA?ATC?ACA?TCT?CCT?AAA?GAG?ACT?TTT?CCC?GAG?GTC?CCT?CGT?421
121?R V M G W G A I T S P K E T F P E V P R 140
421?TGT?GCT?AAC?ATT?AAC?CTG?TTC?GAT?TAT?ACG?GTG?TGT?CGT?GGA?GCT?TTC?TCA?AGG?TTG?CCA?481
141?C A N I N L F D Y T V C R G A F S R L P 160
482?GAG?ACA?AGA?AGA?ATA?TTG?TGT?GCA?GGT?GTC?ATG?GAA?GGA?GGC?ATA?GAT?ACA?TGT?AAT?CAT?541
161?E T R R I L C A G V M E G G I D T C N H 180
542?GAC?TCT?GGG?GGA?CCT?CTC?ATC?TGT?GAT?GGA?CAA?TTC?CAG?GGC?ATT?GTA?TCT?TGG?GGA?CCC?601
181?D S G G P L I C D G Q F Q G I V S W G P 200
602?TAT?CCT?TGT?GCC?CAA?CCA?CGT?AAG?CCT?GCC?CTT?TAC?ACC?AAT?GTC?TTC?AAT?TAT?AAT?GGT?661
201?Y P C A Q P R K P A L Y T N V F N Y N G 220
662?TGG?ATC?CGG?AGC?ATT?ATT?GCC?GGA?AAT?ATC?GAT?GCG?GCT?TGC?CCC?CCG?TGA 709/711
221?W I R S I I A G N I D A A C P P * 236
<210>2
<211>236
<212>PRT
<213〉agkistrodon acutus (Hippocampus kuda Bleeker)
<220>
<221>mat?peptide
<222>(1)…(236)
<400>2
1 V I G G N E C N I N E H R F L V A L Y D 20
21?N L T G T L D C G G T L I N Q E W V L S 40
41?A A H C D R T S V V I Y L G M H N K S V 60
61?N N D D Q Q R R S P K E K Y F F N C S N 80
81?S F T Q L E K D I M L I R L D S P V N N 100
101?S T H I A P L S L P S S P P S M D S V C 120
121?R V M G W G A I T S P K E T F P E V P R 140
141?C A N I N L F D Y T V C R G A F S R L P 160
161?E T R R I L C A G V M E G G I D T C N H 180
181?D S G G P L I C D G Q F Q G I V S W G P 200
201?Y P C A Q P R K P A L Y T N V F N Y N G 220
221?W I R S I I A G N I D A A C P P * 236
Claims (4)
1. with the method for RT-PCR, separate the thrombase-like gene tle that obtains from the total RNA of agkistrodon acutus, its dna sequence dna is as sequence table<400〉shown in 1 sequence.
2. the albumen of the described genes encoding of claim 1, its aminoacid sequence is as<400〉shown in 2 sequences; This molecular weight of albumen is 28kD.
3. the described albumen of claim 2, preparation by the following method:
(1) the described gene tle of claim 1 is cloned on the methanol yeast expression vector pPICZ α A, obtains recombinant expression vector pPICZ α A-tle
(2) pPICZ α A-tle electric shock is transformed Pichi strain GS115, obtain recombination yeast gene engineering fungus;
(3) at the substratum of pH5.5, be 1% methyl alcohol with concentration, above-mentioned recombination yeast gene engineering fungus was carried out abduction delivering 6 days;
(4) fermented supernatant fluid obtains the recombination classes zymoplasm TLE of purifying through Q Sepharose FF anionresin column purification.
4. the described albumen of claim 2 is used for the treatment of the application in the vessel embolism medicines such as phlebothrombosis, cerebral thrombosis in preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100369604A CN100351381C (en) | 2005-09-02 | 2005-09-02 | Novel thrombase-like gene and its use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100369604A CN100351381C (en) | 2005-09-02 | 2005-09-02 | Novel thrombase-like gene and its use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1782083A true CN1782083A (en) | 2006-06-07 |
CN100351381C CN100351381C (en) | 2007-11-28 |
Family
ID=36772694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100369604A Expired - Fee Related CN100351381C (en) | 2005-09-02 | 2005-09-02 | Novel thrombase-like gene and its use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100351381C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102851303A (en) * | 2012-09-24 | 2013-01-02 | 福州大学 | Thrombin-like enzyme gene and application thereof |
CN111455022A (en) * | 2019-10-22 | 2020-07-28 | 上海赛伦生物技术股份有限公司 | Extraction method of trace pallas pit viper venom gene, specificity detection method and kit thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0314096B1 (en) * | 1987-10-29 | 1994-01-12 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
CN1060806C (en) * | 1997-11-12 | 2001-01-17 | 中国科学院上海生物化学研究所 | Gene sequence of fibrin ferment of Agkistrodon acutus snakes |
CN1370833A (en) * | 2001-02-27 | 2002-09-25 | 大连理工大学 | Pit viper venom batroxobin gene cDNA sequence of Dalian Snake Island in Liaoning Prov. of China and its cloning |
JP2002306163A (en) * | 2001-04-11 | 2002-10-22 | Chemo Sero Therapeut Res Inst | Method of preparing gene-recombinant human thrombin using escherichia coil as host |
CN1189559C (en) * | 2003-02-28 | 2005-02-16 | 边六交 | Method for separating and purifying batroxobin from snake venom |
-
2005
- 2005-09-02 CN CNB2005100369604A patent/CN100351381C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102851303A (en) * | 2012-09-24 | 2013-01-02 | 福州大学 | Thrombin-like enzyme gene and application thereof |
CN111455022A (en) * | 2019-10-22 | 2020-07-28 | 上海赛伦生物技术股份有限公司 | Extraction method of trace pallas pit viper venom gene, specificity detection method and kit thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100351381C (en) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100351381C (en) | Novel thrombase-like gene and its use | |
CN101402688A (en) | Fusion protein, encoding gene and uses thereof | |
CN102757973B (en) | cDNA sequence and amino acid sequence of lugworm fibrinolytic enzyme with thrombolysis activity | |
EP2143790B1 (en) | A purified recombinant batroxobin with high specific activity | |
US8017750B2 (en) | Haemocoagulase | |
CN102021160B (en) | Snake venom serine protease and coding gene and application thereof | |
CN1159438C (en) | Ahylysantinfarctase thrombase and its production process | |
CN1563378A (en) | Gene of streptokinase, recombination protein and preparation method | |
CN1370833A (en) | Pit viper venom batroxobin gene cDNA sequence of Dalian Snake Island in Liaoning Prov. of China and its cloning | |
CN1168492C (en) | Methods for treating vascular disorders | |
CN1850976A (en) | Glucose kinase derivant for inhibiting platelet aggregation and thrombase activity, and its preparing method | |
CN1373223A (en) | Cathepsin B gene of bollworm and its clone, recombination and expression techniques | |
CN1548534A (en) | Reptilase and its production process and application | |
CN104131016A (en) | Tenebrio molitor L. trypsin-like enzyme gene nucleotide sequence and cloning method | |
CN1089111C (en) | New catalase, its gene and composite containing it, and its preparation method | |
CN101092612A (en) | New thrombin with hemostaitic activityin in category of snake poison of hundred-paced pit | |
CN1940065A (en) | Oriented mutant gene engineering barr kinase and its use | |
CN1563370A (en) | Antiplasmin of Verticillium lecanii, preparation method and usage | |
CN1294256C (en) | Gene-expressed human tissue kallikrein protein separating and purifying method | |
CN1279170C (en) | Encoding gene sequence of nereid kinase possessing embolus dissolving activity and its amino acid sequence | |
CN101067131A (en) | Affinity chromatographic process of separating and purifying plasmin | |
CN1109891A (en) | Methods for preventing degradation of protein C | |
CN1286974C (en) | Mutant of recombined glucokinase for anti blood platelet collecting and low immunogencity | |
CN1876818A (en) | Recombinant plasmid capable of efficiently expressing human liver growth factor in eukaryotic cell | |
CN1130461C (en) | Recombined new thrombolytic enzyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071128 Termination date: 20160902 |
|
CF01 | Termination of patent right due to non-payment of annual fee |